Regeneron Pharmaceuticals, Inc. REGN

788.04 (7.98) (1.00%) as of 25 Sep
Market cap
$81.3B
P/E
18.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
14.04% 14.55% 14.87% 15.19%

+8 more TTM periods

ROA
10.83% 11.28% 11.50% 11.80%
ROIC
9.34% 9.20% 8.82% 9.14%
Return on Tangible Assets
23.56% 24.08% 24.00% 24.67%
Average Days of Receivables
154.26 140.21 146.10 145.69
Free Cash Flow per Share
34.78 36.45 36.00 37.46
Free Cash Flow
3,575.20 3,791.00 3,765.20 3,881.00
Capital Expenditures
(1,106.10) (1,221.70) (1,213.70) (1,190.00)
Piotroski F-Score
5.00 4.00 4.00 4.00
Other line items
Cash ROIC
11.23% 11.89% 11.70% 12.04%
Accounts Receivable Turnover
2.55 2.64 2.40 2.42
Accounts Payable Turnover
2.50 2.66 2.43 2.97
Inventory Turnover
0.75 0.73 0.67 0.66
Average Days of Payables
179.90 162.59 163.15 158.49
Days of Inventory on Hand
478.62 491.29 556.14 570.67
Tax Rate
(0.16) (0.14) (0.14) (0.11)
Research and Development Expense of Revenue
40.40% 40.66% 40.79% 39.56%
Selling, General and Administrative Expense of Revenue
17.65% 18.20% 18.82% 19.07%
Share Based Compensation of Revenue
6.35% 6.67% 6.93% 7.36%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
1.08 1.13 1.11 1.11
Depreciation/Fixed assets
0.10 0.10 0.11 0.11
Capex/Depreciation
(2.09) (2.26) (2.23) (2.27)
Revenue per Share
151.12 143.46 137.12 137.53
Operating CF per Share
45.54 48.20 47.60 48.95
Capex per Share
(10.76) (11.75) (11.60) (11.49)
Capex to Sales
0.07 0.08 0.08 0.08
Net Profit Margin
27.86% 29.65% 31.41% 32.13%

Fold the line items

Columns are period end dates